Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03926624
Title Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Delta-Fly Pharma, Inc.
Indications

acute myeloid leukemia

Therapies

Decitabine + Venetoclax

Azacitidine + Venetoclax

Cytarabine + Filgrastim + Fludarabine + Idarubicin

Cytarabine + Venetoclax

Cytarabine + Filgrastim + Fludarabine

Decitabine

Azacitidine

Cladribine + Cytarabine + Filgrastim + Mitoxantrone

DFP-10917

Cladribine + Cytarabine + Filgrastim + Idarubicin

Cytarabine

Cytarabine + Etoposide + Mitoxantrone

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.